Navigation Links
Targanta Initiates Phase 2 Oritavancin Infrequent Dosing Study
Date:9/13/2007

SIMPLIFI to Examine Single-Dose and Infrequent-Dosing Regimens in cSSSI

CAMBRIDGE, Mass., Sept. 13 /PRNewswire/ -- Targanta Therapeutics Corporation today announced the initiation of its Phase 2 trial investigating the safety and efficacy of oritavancin at Single or Infrequent Doses for the Treatment of Complicated Skin and Skin Structure Infections (cSSSI), or SIMPLIFI. Oritavancin is Targanta's lead antibiotic candidate targeting gram- positive infections.

This Phase 2 study is an international, multi-center, randomized, double- blind, controlled study in patients with cSSSI presumed or proven to be caused by gram-positive pathogen(s). The study consists of three treatment arms in which patients will receive either:

-- 200 mg oritavancin IV daily for a minimum of 3 days and up to a maximum

of 7 days (the dosing regimen used in the larger of the two completed

Phase 3 studies of oritavancin in cSSSI);

-- A single dose of 1200 mg oritavancin IV; or

-- A single dose of 800 mg oritavancin IV, with a further dose of 400 mg

IV on Day 5 if needed.

As its primary endpoint, SIMPLIFI will measure clinical response (either cure or improvement versus failure) in clinically evaluable patients. As a secondary endpoint, this study will examine safety data in all intent-to-treat patients. Targanta expects to enroll a total of 300 patients in this study.

"Based on extensive pharmacokinetic and pharmacodynamic modeling, we believe there is a high likelihood of success with the less frequent oritavancin dosing regimens being studied here," said Pierre E. G. Etienne, M.D. Chief Development Officer of Targanta. "We currently expect to complete collection of clinical trial data from SIMPLIFI in the second half of 2008, at which time we will assess the outcomes and determine whether to pursue Phase 3 registration trials. In the meantime, we are working on the preparation of our first U.S. and European regulatory s
'/>"/>

SOURCE Targanta Therapeutics Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Targanta Study Shows Oritavancin Treatment Effective in a Mouse Model of Anthrax
2. Targanta Reports Improved Ability of Oritavancin to Stop Bacteria Growth In Vitro Compared With Other Glycopeptide Antibiotics
3. Malvern initiates European user group meetings for chemical imaging
4. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
5. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... YORK , Sept. 18, 2014 This BCC Research ... share of major players, market growth and size, and opportunities ... trends and revenue through 2018. Patent analysis in the report ... as the U.S., Europe and ... to: - Define and discuss the global medical device technologies ...
(Date:9/18/2014)... Sept. 18, 2014   Fruit Street Health ... initial seed round of funding. The ... by a series of individual investors, the majority of ... in the initial round are; Houston Cardiology Consultants ... Urologist Stacy Childs, Rapha Family Medicine Practice Owner ...
(Date:9/18/2014)... 2014  ADM Tronics Unlimited, Inc. (OTCQB: ADMT) ... its corporate Advisory Board for business development. ... Harvard Medical School and Visiting Professor at the ... Masters degree in Electronics Engineering and his Ph.D. ... Bologna. After spending a year as a visiting ...
Breaking Medicine Technology:Medical Devices: Technologies and Global Markets 2Medical Devices: Technologies and Global Markets 3Medical Devices: Technologies and Global Markets 4Fruit Street Health Secures First Round Of Seed Funding Led By Group Of Medical Industry And Technology Leaders 2Fruit Street Health Secures First Round Of Seed Funding Led By Group Of Medical Industry And Technology Leaders 3ADM Tronics Appoints Gianluca DeNovi, Ph.D. To Advisory Board 2ADM Tronics Appoints Gianluca DeNovi, Ph.D. To Advisory Board 3
... ADDISON, Texas, March 11, 2011 U LURUInc.(NYSE ... the development of a portfolio of wound management and oral ... NYSE Amex LLC (the "Exchange") advising ULURU that it is ... continued listing standards under Section 1003 of the Exchange,s Company ...
... (Nasdaq: NVAX ), a clinical-stage vaccine company, announced ... be presenting at the ROTH 23rd Annual OC Growth Stock ... at The Ritz Carlton, Laguna Niguel, CA.  A live audio-only ... Company website at www.novavax.com under Investors/Events, and a ...
Cached Medicine Technology:ULURU Inc. Receives Letter of Non-Compliance From NYSE Amex 2
(Date:9/19/2014)... 19, 2014 AttorneyOne.com, a recognized authority on ... from the FDA on Potassium Chloride . , ... recalled one lot of Potassium Chloride Injection 10mEq ... cartons. Potassium Chloride, administered intravenously, is used to treat potassium ... on a labeling error on the shipping cartons in a ...
(Date:9/19/2014)... Yisrayl Hawkins, Pastor of The House of ... need to protect children. He begins by encouraging the reader ... reminds that there are many other children, like Michael Brown, ... spreading faster than cancer all over the world and must ... to seven billion Michaels in the world who were left ...
(Date:9/19/2014)... VogueQueen.com has recently unveiled a ... ladies more beautiful at their weddings. The new range ... The company’s new products are made for the coming ... for all the global clients. , “The ... have ordered several items on its website. I'm very ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 Defendants ... http://www.xareltolawsuitcenter.com ) currently pending in Pennsylvania’s Philadelphia Court ... claims filed on behalf of out-of-state plaintiffs dismissed, ... on September 11th, the defendants maintain that circumstances ... in the lawsuits have no connection to Pennsylvania. ...
(Date:9/18/2014)... 2014 Dr. David A. F. Ellis ... American Academy of Facial Plastic and Reconstructive Surgery and ... Division of Facial Plastic Surgery. He is recognized ... surgery. , Dr. Ellis will be presenting on ... presenting on injection techniques and various treatments for complications ...
Breaking Medicine News(10 mins):Health News:Baxter Recalls Potassium Chloride Injection: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Yisrayl Hawkins Says the Michael Brown Scenario Will Continue Without Swift Action in New Post 2Health News:VogueQueen.com’s New Line Of Cheap Wedding Dresses Aims To Attract Chic Ladies 2Health News:Xarelto Lawsuit Defendants Seek to Have Pennsylvania Claims Filed by Out-of-State Plaintiffs Dismissed, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit Defendants Seek to Have Pennsylvania Claims Filed by Out-of-State Plaintiffs Dismissed, Bernstein Liebhard LLP Reports 3Health News:Dr. David A. F. Ellis Has Been Invited to Speak at a Conference of the American Academy of Facial Plastic and Reconstructive Surgery in Orlando, Florida 2
... , 221.10.254.64 (Garrison, NY) Concern about the capacity ... studies has largely focused on impairment due to psychotic ... given to the cognitive errors that prospective participants make ... In a study reported in IRB: ...
... HealthDay Reporter , MONDAY, Aug. 8 (HealthDay ... say that elderly lung cancer patients can gain significant ... in younger patients. The finding raises questions about ... American Society of Clinical Oncology in 2004, which advised ...
... There are increasing pressures for health care providers ... policy making. But Canadians are more likely to allow ... that their privacy is protected. A new report by ... Electronic Health Information at the University of Ottawa and ...
... Aug. 8 (HealthDay News) -- One reason why people worldwide ... be because the games allow them to "try on" characteristics ... The research included hundreds of casual game players and nearly ... for playing, as well as their post-game emotions. The ...
... HealthDay Reporter , MONDAY, Aug. 8 (HealthDay News) -- At ... diagnose heart disease is found to have major blockages requiring ... few are found to have a major blockage when undergoing ... procedures, according to a study in the Aug. 16 issue ...
... published in the August issue of the Journal of ... in the number of laparoscopic bariatric procedures, an increase in ... mortality rates between 2003 and 2008. During the past decade, ... authors concluded that these trends are due, in part, to ...
Cached Medicine News:Health News:Schizophrenia study finds cognitive deficits significantly impair decision-making capacity 2Health News:Elderly Lung Cancer Patients Can Gain From Two-Drug Chemo: Study 2Health News:Elderly Lung Cancer Patients Can Gain From Two-Drug Chemo: Study 3Health News:Most Canadians can be uniquely identified from their date of birth and postal code 2Health News:Hospitals Vary Widely in Rate of Heart Procedures: Study 2Health News:Hospitals Vary Widely in Rate of Heart Procedures: Study 3Health News:Number of laparoscopic bariatric procedures continued to rise between 2003-2008 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: